Table 2 Relative risk (RR) for selected cancers beyond the first year of follow-up among patients previously hospitalised for herpes zoster; follow-up started 2 months after the date of discharge with herpes zoster

From: The risk and prognosis of cancer after hospitalisation for herpes zoster: a population-based follow-up study

 

Observed

RR

95% CIa

All malignant neoplasms

1239

1.1

1.1–1.2

Haematological cancers

111

1.7

1.4–2.0

Non-Hodgkin's lymphomab

38

1.6

1.1–2.2

Hodgkin's lymphoma

6

3.0

1.1–6.6

Multiple myeloma

22

1.7

1.1–2.6

Leukaemia

45

1.7

1.2–2.2

Immune-related cancers

251

1.1

1.0–1.2

Liver

13

1.3

0.7–2.2

Cervix

11

0.8

0.4–1.5

Nonmelanoma skin cancer

203

1.1

1.0–1.3

Malignant melanoma

15

0.8

0.5–1.3

Sarcomac

9

1.1

0.5–2.1

All other sites d

877

1.1

1.0–1.2

Brain

29

1.6

1.1–2.3

Oesophagus

16

1.5

0.9–2.4

Stomach

44

1.3

0.9–1.7

Colon

97

0.9

0.7–1.1

Rectum

48

0.9

0.7–1.2

Pancreas

39

1.2

0.8–1.6

Lung

130

1.2

1.0–1.4

Breast

127

1.1

0.9–1.3

Corpus uteri

24

1.0

0.6–1.4

Ovary

23

1.1

0.7–1.6

Prostate

79

1.2

0.9–1.4

Kidney

32

1.3

0.9–1.8

Bladder

59

1.0

0.7–1.2

  1. aCI denotes confidence interval.
  2. bNon-Hodgkin's lymphoma is also classified as an immune-related cancer.
  3. cAmong sarcomas, only Kaposi's sarcoma is regarded as an immune-related cancer.
  4. dOnly selected sites are specified.
Back to article page